What is HC Wainwright’s Forecast for Clene FY2028 Earnings?

Clene Inc. (NASDAQ:CLNN) – Investment analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for shares of Clene in a note issued to investors on Monday, March 24th. HC Wainwright analyst J. Pantginis now expects that the company will earn $5.26 per share for the year, down from their prior forecast of $5.53. HC Wainwright has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price target on shares of Clene in a research note on Monday. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $55.25.

Clene Stock Up 2.3 %

CLNN stock opened at $3.54 on Tuesday. The company has a market capitalization of $29.47 million, a P/E ratio of -0.67 and a beta of 0.27. The company has a 50-day simple moving average of $4.49 and a 200 day simple moving average of $4.88. Clene has a fifty-two week low of $3.37 and a fifty-two week high of $9.20.

Clene (NASDAQ:CLNN) last released its quarterly earnings results on Monday, March 24th. The company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by ($0.46). The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.13 million. Clene had a negative return on equity of 1,106.30% and a negative net margin of 8,556.77%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CLNN. SBI Securities Co. Ltd. bought a new stake in Clene in the fourth quarter worth about $69,000. Fullcircle Wealth LLC bought a new position in shares of Clene during the 4th quarter valued at about $69,000. Renaissance Technologies LLC acquired a new position in shares of Clene in the 4th quarter worth approximately $96,000. Parsons Capital Management Inc. RI bought a new stake in shares of Clene in the 4th quarter worth approximately $194,000. Finally, Geode Capital Management LLC lifted its stake in Clene by 52.9% during the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after purchasing an additional 22,539 shares during the last quarter. Institutional investors own 23.28% of the company’s stock.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.